55.2 percent of induction responder patients treated with STELARA at the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without corticosteroids Overall, 79.1 percent of patients treated with STELARA in the long-term extension (LTE) who were receiving corticosteroids at maintenance baseline were no longer receiving corticosteroids by week 200
